Thank you very much, Mr. Chair.
I always enjoy listening to Mr. Davies' rationale, but there has been a lot of talk about the House motion. Let me read the following from the House motion:
(y) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the COVID-19 Vaccine Task Force and its subcommittees;
(z) an order of the House do issue for all memoranda, e-mails, documents, notes and other records relating to the Government of Canada’s COVID-19 vaccine distribution and monitoring strategy, including, but not limited to anticipated timelines for the distribution of an approved COVID-19 vaccine across Canada and the prioritization of population groups for vaccination;
(aa) all documents issued pursuant to this order (i) be organized by department and be provided to the Office of the Law Clerk and Parliamentary Counsel within 15 days of the adoption of this order, (ii) be vetted for matters of personal privacy information, and national security, and, with respect to paragraph (y) only, be additionally vetted for information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations between the Government of Canada and a third party, by the Law Clerk and Parliamentary Counsel within seven days of the receipt of the documents, (iii) be laid upon the table by the Speaker, at the next earliest opportunity, once vetted, and permanently referred to the Standing Committee on Health;
I don't want to put words in Mr. Davies' mouth, but I thought I heard him say something along the lines that the House motion was going to dictate that we would get these anyway. I am not a lawyer. I know that Dr. Powlowski and Mr. Davies are both lawyers, so those statements would have meant a lot more to them than they did to me, but I don't see the mention of contracts in there.
Mr. Chair, transparency and accountability, as we've said many, many times, are extremely important to this government. Minister Anand and others have also said that we're committed to releasing as much information as possible on all of our efforts throughout this pandemic, without putting access to supplies, including vaccines, at risk. We're providing information publicly on the vaccine delivery schedules.
I have to tip my hat, if I may, to Major-General Dany Fortin. Every day he is in front of the press and in front of Canadians, stating that, with the best information he has, this is what's coming out this week and this is what's going to be sent, as working numbers, to each province and each territory. I understand that there is not a single country out there doing that level of work. I don't think that's something he had to do, but I do think it's something he chose to do so that provinces could be as prepared as possible, knowing full well that there could be bumps in the road and knowing full well that the numbers were working numbers.
Speaking of numbers, we hear now that after the 15th we'll start to get 400,000 to 470,000, or something like that, per week until the end of March so that we can hit those totals that we need to hit. Providing those deliveries week by week to provinces and territories gives them a chance to plan for their delivery operations. Again, no other country is putting out publicly the weekly delivery schedules.
The minister spoke about this heavily at her appearance and she explained why. I think she also mentioned, although I don't want to put words in the minister's mouth, a non-disclosure agreement. We've heard comments about copies of contracts in other countries that were released. I was told by someone that the entire contract was just about completely redacted and blacked out to the point that there was very little information in that contract. A contract is an agreement between two parties. One party can't choose to arbitrarily, in my opinion, share that information until the other party suggests that is okay. I believe there is a non-disclosure agreement within that.
Mr. Chair, we've all lived our lives in the shadow of this virus over the past year. Canadians have experienced isolation, uncertainty and heartbreak. All of us on this committee can talk about how we've missed seeing our friends. We're all type A personalities. We're huggers. We're high-fivers. We're handshakers.
Like all of you, I'm locked in a small room and on Zoom all day long. I miss family. I miss friends and extended family. We have communities that have lost businesses or have businesses that have trouble making ends meet. We've seen communities band together. Here in Nova Scotia, we have our own little bubble, and we've been very successful, because the members of our communities bought early into public health guidelines. They truly did, because they love their neighbours, they love their communities and they love their families.
They're taking it so seriously that we've had extremely low numbers, but again, many businesses have gone out of business or have had trouble making ends meet, and we have lost many loved ones to this horrible pandemic. We're seeing the pandemic continue, and we're seeing it continue to take a toll on Canadians, but we are seeing the numbers go down. We're seeing the numbers go down since the increase in January—and that's a good sign—and we're seeing safe and effective vaccines being rolled out across the country.
We know how difficult this has been, and we all just want this pandemic to end. As vaccinations roll out among those in our communities who are most at risk of infection, we need to keep following the measures that prevent the spread of this virus and its variants. We know what worked in the first wave. We just need to buckle down and continue to do that.
Mr. Chair, from the beginning of this pandemic, the government has been keeping Canadians safe by acquiring PPE—we've talked about that at our committee in the past—and supplies in a very competitive worldwide market. I think we all heard very clearly that every country was staking out their territory to get as much PPE as they possibly could in the early days.
We continue to work non-stop in negotiating access to hundreds of millions of doses of vaccines. We heard Mr. Kelloway talk about this, and we heard Mr. Barlow reiterate what Mr. Kelloway said with regard to the portfolio of vaccine companies that we've dealt with, and again, in an atmosphere that is very volatile and very complex, with a bunch of countries staking out their claims.
Mr. Chair, Canadians across the country have been taking to heart the guidance from our public health officials and, as I said for Nova Scotians, truly putting it into action. This spirit of co-operation has been crucial as our first line of defence to keep our neighbours and communities safe.
We all know that the only way to get us through this marathon of the pandemic is to get vaccines to all Canadians who want one. Every member of this committee understands that and knows how important that is. That has been the goal of our strategy: making sure that safe and effective vaccines can be delivered, distributed and administered as soon as we could acquire them.
Mr. Chair, it's a strategy that we've been putting into action for a long time. The fact of getting these vaccines to Canadians in a timely manner means that we are competing with that entire world, that market, that competitive market of countries of the world again staking out their claim to vaccines, showing that vaccines are such an incredibly precious commodity.
We've been approaching companies from around the world. As soon as their vaccine candidates began to show some promise, we would ink a contract with them, knowing full well that there could be bumps in the road and not knowing in advance, way back in the early days of the pandemic...because, Mr. Chair, I don't think there's much evidence in history of vaccines being developed, approved and sent around the world and to the provinces and territories 11 months after a pandemic has hit. Again, I'd like to give some kudos to the scientific world. It's absolutely incredible what this world was able to accomplish in getting vaccines developed, approved, manufactured and sent out to countries all around the world.
We knew that an approach based on the most recent scientific developments...and thanks to the COVID-19 vaccine task force, we had access to advice from leading experts in vaccines and immunology to alert us to the best candidates. Of course, we've signed with seven of those best candidates. We got commitments and signed flexible agreements with seven vaccine manufacturers, starting with Moderna in July, a long time ago. Again, I'm going back to the point that it was July, six months after a pandemic hits. That's absolutely amazing.
This government then went on to get access to millions of doses, to put in options on our purchase agreements for millions and millions more. By ensuring access to nearly 400 million doses of potential vaccines from seven different manufacturers, our strategy is set to deliver for Canadians.
Mr. Chair, I'm proud to say that experts across Canada and around the world agree with this approach. These include Dr. Zain Chagla of McMaster University, Dr. Jason Kindrachuk of the University of Manitoba, and health law professor Lorian Hardcastle at the University of Calgary. Susan Athey of Stanford University has called Canada a “role model”. By building, as Mr. Kelloway says, that diverse portfolio of vaccines, we have positioned Canada to be able to deploy vaccines as quickly as possible.
Mr. Chair, this approach is providing much-needed security to communities across Canada. Shipments of Moderna and Pfizer vaccines have been arriving. Our most vulnerable people in long-term care homes and health care workers are being vaccinated. Working together with the provinces and territories, we've received and distributed a total of 1.4 million COVID-19 vaccine doses, with Canadians getting their first dose and more being inoculated every day. However, the road continues to be long. We do need to anticipate that things can go wrong in what is proving to be an unstable and unpredictable marketplace. Countries are clamouring to get the doses they negotiated for, as I said earlier, as fast as possible, and Canada is no exception.
Again, it's an extremely pressurized environment. We know and we've seen that there will be bumps. I think the Prime Minister and the government have remained vigilant. They have been in contact nearly every day with the CEOs at these companies. They've reassured us that they will meet their commitments for the first quarter of this year. That means Pfizer will still deliver a total of four million doses, and Moderna two million, by the end of March.
Mr. Chair, Canada is hardly alone in facing obstacles in receiving vaccines, but this is what our strategy was designed for. Having a number of agreements in place, building a diverse portfolio and keeping arrangements flexible are helping to bring stability to a really chaotic situation. While the numbers may fluctuate in the short term, manufacturers will continue to find efficiencies as they produce. We've seen already that Pfizer has had to upgrade their facility in order to be able to produce more and more doses for distribution around the world. This government remains committed to sharing accurate information as soon as we get it. As more doses are produced, the system for manufacturing and distributing vaccines will stabilize.
Mr. Chair, I know that every member of this committee, just like all Canadians, wants to see an end to this terrible pandemic. Any time we hear of delays in getting vaccine shipments, the frustration grows, but we've put Canada on the right track with a strategy for acquiring vaccines that combines diversification, flexibility and aggressive negotiating. When setbacks occur, we're committed to keeping Canadians informed and redoubling our efforts to get shipments back on schedule.
As we've said before, the race to end this pandemic has been a marathon more than a sprint. Now more than ever, all the members of this committee need to conserve our energy for fighting the virus for Canadians, and not each other. If we work together now, we'll be able to get together soon—I like that line—and more safely. We will get through this.
Thank you very much, Mr. Chair.